The anticipation surrounding dose optimization data for Pfizer (NYSE:PFE)'s obesity treatment, danuglipron, was also mentioned as a point of interest for the first quarter. However, the analyst ...
Pfizer's Q4 2024 earnings beat expectations, but concerns over 2025 guidance and patent expirations led to stock decline. See ...
Dividend stocks have remained a focal point for investors, especially amid market volatility and the growing need for steady ...
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows ...
Welch Group LLC cut its stake in Pfizer Inc. (NYSE:PFE – Free Report) by 35.1% in the fourth quarter, HoldingsChannel reports ...
Drug major Pfizer Inc. (PFE), while reporting a profit in its fourth quarter, compared to prior year's loss, on Tuesday reaffirmed ...
Despite a significant year-over-year decline in Comirnaty revenue, the overall performance was strong, driven by growth in non-COVID-19 products and strategic acquisitions. Pfizer, a renowned ...
Pfizer (NYSE:PFE – Get Free Report) had its price objective decreased by equities research analysts at Citigroup from $30.00 ...
Earnings season is in full swing in the pharma sector with major players sharing their latest results. On Tuesday (February 4 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback